METHODS:
A literature review identified all randomized, controlled A and T trials for MBC. Progression-based endpoints were classified by prospective definitions. Treatment effects were derived as hazard ratios (HR) for PFS (HRPFS) and OS (HROS) from trial data (constant rate assumption). The kappa statistic assessed overall agreement. HROS was predicted from trial HRPFS using fixed effects models that were internally validated. Sensitivity and subgroup analyses were performed for the constant rate assumption, PFS definition, year of last patient recruitment, and line of treatment. RESULTS: Inclusion criteria were met by 15 A and 16 T trials, allowing 17 A (n = 4155) and 17 T (n = 5509) comparisons. The direction of HROS and HRPFS agreed in 25% (A) to 50% (T) (negative) and in 62.5% (A) to 50% (T) (positive) (kappa = 0.71, p = 0.0029 (A); kappa = 0.75, p = 0.0028 (T)). HRPFS was a significant predictor of HROS for A (p = 0.0019) and T (p = 0.012) in the fixed effects models, with explained variance (R 2 ) of 0.35 (T) and 0.49 (A). Cross validation showed that 97% of the 95% prediction intervals crossed the equivalence line. The direction of predicted HROS agreed with observed HROS in 82% (A) and 76% (T). Results were robust in sensitivity and subgroup analyses. CONCLUSION: This analysis suggests the treatment effect on PFS is significantly associated with the treatment effect on OS. However, prediction of OS based on PFS is surrounded with uncertainty: Half (A) to one third (T) of the OS treatment effect variance is explained by the PFS treatment effect variance. Using limited data, sensitivity and subgroup analysis did not explain result heterogeneity.
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PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)
Mallick R 1 , Hudes G 2 , Levy DE 3 1 Wyeth Research, Collegeville, PA, USA, 2 Fox Chase Cancer Center, Philadelphia, PA, USA, 3 Wyeth Pharmaceuticals, Cambridge, MA, USA OBJECTIVES: To evaluate if quality-adjusted survival for temsirolimus (TEMSR) met criteria for minimal clinically important difference (MCID) in a randomized, outpatient study of first-line treatment of patients with poor-prognosis, advanced renal cell carcinoma (RCC). In this study TEMSR (25 mg IV once-weekly) was associated with median 10.9 months overall survival (OS) compared with median 7.3 months OS for interferon (IFN) (up to 18 MU subcutaneously thrice weekly (p = 0.008). METHODS: OS was partitioned into 3 distinct periods: a) time in serious toxicity (aggregated time in grade 3 or 4 adverse events (AEs); b) time in progression (based on tumor response assessment); and c) time without symptoms of progression or toxicity (TWiST). Based on patient-reported responses to the EuroQol (EQ-5D) at representative time points during each period, Q-TWiST was estimated as the measure of quality-adjusted survival. Treatment group differences in Q-TWiST were evaluated in terms of restricted means, with patient follow-up truncated at the median of 17.9 months. Variance and covariance were estimated using bootstrap methods. Following published literature, the clinical importance of the TEMSR-IFN difference in Q-TWIST was the percentage obtained when this difference was divided by mean OS for IFN (the control group). RESULTS: All 626 randomized patients were included in computation of health state durations. Response rates for the EQ-5D were 87% (260/300) during progression, 40% (230/570) during toxicity, and 99% (278/279) during TWiST. Patients in the TEMSR group had 1.3 months greater Q-TWiST than those in the IFN group (TEMSR = 7.0 months vs. IFN = 5.7 months; p = 0.0015). The MCID was 14.8% (1.3 months divided by 8.8 months [IFN mean OS]), which is within the published range of 10-15% for MCID in cancer trials. CONCLUSION: Patients with advanced RCC receiving TEMSR met criteria for clinically important improvement in quality-adjusted survival.
PCN65
RESULTS FROM MABEL: QUALITY OF LIFE OF PATIENTS WITH METASTATIC COLORECTAL CARCINOMA (MCRC)
Glynne-Jones R 1 , Esser R 2 , Ralston SJ 3 1 Mount Vernon Hospital, Northwood, Middlesex, UK, 2 Merck KGaA, Darmstadt, Germany, 3 Merck Serono, Feltham, Middlesex, UK OBJECTIVES: The MABEL study is an open label, uncontrolled, multi-centre, study of cetuximab in combination with irinotecan in patients with EGFR expressing mCRC and having progressed on a recent irinotecan-based treatment regimen. A study objective was to assess quality of life (QoL). This abstract will report on findings on 126 patients from 28 UK sites. METHODS: QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EQ-5D. The QLQ-C30 questionnaire comprises 30 items, organised into global health status, functionality, symptomatology and single items. The EQ-5D questionnaire consists of the EQ-5D descriptive system and the Visual Analogue Scale (VAS). QoL changes were assessed on patients with a baseline and at least one post-baseline assessment. RESULTS: At the 6 week assessment, 88 [69.8%] patients completed at least one QoL item, with 71 [56.3%] patients at 12 weeks, and 41 [32.5%] patients at the end of the study visit. Given the loss of two thirds of data by the end of study, the following results will assess data over a 12 week period. Between baseline and 12 weeks the EORTC QLQ-C30 global health score increased slightly from 65.3-68.9. Symptomatic scales reported a similar trend with the exception of diarrhoea and financial difficulties single items. The EQ-5D index and VAS also reported a trend for a slight improvement between baseline (0.73 and 0.90 respectively) and 12 weeks (0.77 and 0.93 respectively.) CONCLU-SION: It is important to consider these results in context of patient prognosis and treatment administered. The data suggests
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